Key statistics
On Wednesday, Avalo Therapeutics Inc (AVTX:NAQ) closed at 9.03, 128.60% above the 52 week low of 3.95 set on Jan 17, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 9.05 |
---|---|
High | 9.80 |
Low | 9.03 |
Bid | 7.00 |
Offer | 10.15 |
Previous close | 9.63 |
Average volume | 18.15k |
---|---|
Shares outstanding | 9.68m |
Free float | 9.51m |
P/E (TTM) | -- |
Market cap | 93.24m USD |
EPS (TTM) | -63.82 USD |
Data delayed at least 15 minutes, as of Oct 09 2024 20:48 BST.
More ▼
Announcements
- Avalo Announces First Patient Dosed in Phase 2 LOTUS Trial of AVTX-009 for the Treatment of Hidradenitis Suppurativa
- Avalo Announces Participation in September Investor Conferences
- Avalo Reports Second Quarter 2024 Financial Results and Provides Business Updates
- Avalo Therapeutics Announces Appointment of Dr. Mittie Doyle as Chief Medical Officer
- Avalo Therapeutics Announces Active IND for AVTX-009, an anti-IL-1β mAb, to Treat Hidradenitis Suppurativa
- Avalo Therapeutics Announces Appointment of Paul Varki as Chief Legal Officer
- Avalo to Present at the Oppenheimer Novel Targets in Immunology Summit
- Avalo Reports First Quarter 2024 Financial Results and Provides Business Updates
- Avalo Therapeutics Appoints Biotech Leaders to Board of Directors
- Avalo Reports 2023 Financial Results and Provides Business Updates
More ▼